secwatch.observer — SEC 8-K summary
======================================

Issuer:     SUPERNUS PHARMACEUTICALS, INC. (SUPN)
CIK:        0001356576
Form:       8-K
Filed at:   2024-11-04T23:59:59+00:00
Accession:  0001356576-24-000065
Event type: earnings
Sentiment:  positive
Materiality: 0.80
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Supernus Q3 revenue $175.7M (+14% YoY); raises FY guidance; Qelbree sales +68%
------------------------------------------------------------------------------

- Net sales of Qelbree $62.4M (+68% YoY); GOCOVRI $35.6M (+8% YoY) in Q3 2024.
- Total revenue $175.7M (+14% YoY); operating earnings $40.9M; adjusted operating earnings $67.7M.
- Raising full year 2024 guidance for total revenues and operating earnings (GAAP and Non-GAAP).
- SPN-820 Phase 2a in MDD: rapid decrease in depressive symptoms, 80% decrease in suicidal ideation; Phase 2b data H1 2025.
- SPN-817 Phase 2a in treatment-resistant seizures: 56% median seizure reduction; Phase 2b expected start by end 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1356576/000135657624000065/0001356576-24-000065-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1356576/000135657624000065/supn-20241104.htm
  HTML page:      https://secwatch.observer/filing/0001356576-24-000065

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer